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Background: To analyze the prevalence and location of tooth loss in Sjögren’s syndrome (SS) patients and com-
pare them with an age- and gender-matched control group. 
Material and Methods: Dental charts and x-rays of 108 (SS) patients were retrieved from an academic dental 
center and special care dentistry department. For each SS patient, an age- and gender-matched non-SS patient 
was randomly selected. Medication, number of extractions and date and location of extractions were assessed. 
Differences between SS and non-SS patients were analyzed using Mann-Whitney U tests, Chi-square tests and 
Fisher’s exact tests. 
Results: Significantly more SS patients were edentulous compared to the non-SS group (14.8% versus 1.9%, p = 
0.001). SS patients had a 61% higher risk to have experienced one or more extractions than control patients. In the 
SS group, there was a non-significant tendency for more maxillary teeth to have been extracted than mandibular 
teeth (42:34). In the control group, the number of extractions in the maxilla and mandible were comparable (21:20). 
When divided into sextants, the number of SS patients with one or more extractions was significantly higher than 
for non-SS patients for each sextant (p = 0.001 to p = 0.032). The largest difference in the proportion of patients 
with one or more extractions between the SS and non-SS patients occurred in the upper anterior sextant (3.4 times 
more frequent).
Conclusions: SS patients are more prone to experience dental extractions compared to patients without SS. It could 
be speculated that this is related to a decreased salivary secretion.
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Introduction 
Sjögren’s syndrome (SS) is a progressive autoimmune 
disorder that causes chronic inflammation and irrevers-
ible damage to the exocrine glands (1). The syndrome 
is classified as either primary or secondary SS (pSS, 
sSS). Secondary SS is accompanied by other autoim-
mune diseases such as rheumatoid arthritis, systemic 
sclerosis, antiphospholipid syndrome or systemic lupus 
erythematosus (2). SS is more prominent in women than 
in men (9:1 ratio) (3). 
The parotid, submandibular and the sublingual glands 
induce the most salivary flow in the oral cavity. In ad-
dition, approximately 800 accessory glands contribute 
to the saliva flow. In SS patients, the salivary flow is 
impaired due to glandular destruction. The current 
theory is that a combination of sex hormones, genetic 
disposition and environmental factors are involved in 
the pathogenesis of SS (4). The initial glandular inflam-
mation is triggered by an immune response that subse-
quently activates T and B cells. This immune response 
leads to an autoantibody activation that causes tissue 
destruction and thereby reduces the salivary flow. How-
ever, it must be noted that the full pathogeneses of SS 
still remain to be discovered and nowadays no scientifi-
cally proven therapy exists for SS (5,6). 
In SS patients, the sublingual and submandibular glands 
are often the first to be affected and in most cases de-
gradation of the salivary glands occurs bilaterally (7-
9). Due to its progressive nature, SS causes a gradual 
reduction in the salivary flow. When the unstimulated 
saliva secretion rate falls below 0.1 mL/min, this is usu-
ally regarded as hyposalivation (10). Hyposalivation can 
cause eating and swallowing problems, lack of taste, 
speech problems, and bacterial or fungal inflammations 
of the oral mucosa (11,12). Furthermore, hyposalivation 
can result in reduced retentiveness of prosthetic appli-
ances and the dry oral mucosa can be very sensitive, 
which makes it difficult or even impossible for SS pa-
tients to wear mucosal supported removable prostheses. 
Saliva is crucial for the maintenance of the oral health 
as it contains a variety of immunoglobulins and anti-
bacterial proteins that protect and lubricate the mouth 
and throat (13).  Furthermore, saliva acts as a buffer and 
supports the re-mineralization of enamel (14).
Due to the lower salivary pH, reduced buffer capacity 
and decreased anti-bacterial potency of saliva, patients 
with SS have a higher risk of developing dental caries 
and erosion, in particular the cervical, buccal and inci-
sal sides of the teeth are commonly affected (13). Fur-
thermore, recent studies have reported that SS patients 
might have a higher risk of developing periodontal dis-
ease. However current literature on the topic remains 
contradictory (15-18).
To date there is still little information on the average 
tooth loss in SS patients (19). Such information would 
be beneficial because it would offer clinicians the pos-
sibility to predict the location of tooth loss and adjust 
their treatment plans accordingly. Furthermore, such 
information could contribute to the development of den-
tal protocols for SS patients. Based on clinical experi-
ence it can be hypothesized that SS patients lose their 
teeth faster than non-SS patients as a consequence of 
the decreased salivary secretion. Therefore, the aim of 
this study was to evaluate tooth loss in SS patients and 




An, age- and gender-matched, retrospective cohort was 
used in this study. The study population comprised 108 
SS patients and a control group of 107 age and gender 
matched non-SS patients. All SS patients included in 
the study were diagnosed with primary or secondary SS 
according to the American-European Consensus Group 
classification Criteria for SS (20). The minimum follow-
up period was 3 years. All patients with a history of 
radiation therapy in the head and neck region, HIV, sar-
coidosis, lymphoma or graft-versus-host disease, were 
excluded. This study followed the Declaration of Hel-
sinki on medical protocol and ethics and the data was 
collected in accordance to the guidelines of the Medical 
Ethical Committee of the VU University Medical Cen-
ter. The Ethics Review Committee of the VU Univer-
sity Amsterdam confirmed that the Medical Research 
Involving Human Subjects Act (WMO) does not apply 
to this study. The reporting of this study conforms to 
the STROBE statement (21).
Variables The primary outcome measure was the num-
ber and location of tooth extractions. Patient age, gen-
der, medication, and date of extractions were assessed. 
Data collection methods Case report forms (CRFs) were 
designed to collect data in a standardized manner. Three 
data abstractor, with specialized knowledge in the field 
of SS and the research question (FM,JV,AW), abstrac-
ted data from all patients records. In order to prevent 
incorrect transfer of patient data from the medical re-
cords to the case report forms, random checks were per-
formed prior to data entry. This was done according to 
the 100-20 rule in which 100% of the data is checked in 
20% of the CRF’s and 20% of the most important data 
was checked in 100% of the CRF’s to prevent mistakes 
in data retrieval (21,22).
- Data analysis As this was not a prospective but a ret-
rospective case-series study, in which a convenience 
sample comprising all patients from a dental school was 
described, a sample size analysis was not performed. 
Differences between SS and control patients were ana-
lyzed using Mann-Whitney U-test, Chi-square tests and 
Fisher’s exact tests. A significance level (α) of 0.05 was 
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chosen. Statistical analysis was performed using SPSS, 
version 23.0 (IBM Corp, Armonk, NY, USA).
Results
- Patients
The size of the study population was based on the num-
ber of patients with SS who fulfilled the aforementioned 
inclusion criteria. Most of the patients (89%) were fe-
male. The average age of the patients was 66.5 years 
(range 34.7-94.2). The study population consisted of 57 
patients diagnosed with pSS (52.8%) and 51 patients di-
agnosed with sSS (47.2%). When comparing the age of 
the pSS with the sSS patients, the latter group was sig-
nificantly older (p=0.005).
The SS group comprised of patients who had been en-
rolled at the Academic Center for Dentistry Amsterdam 
(ACTA) or the Center for Special Care Dentistry Amster-
dam (Stichting Bijzondere Tandheelkunde), for an aver-
age of 8.6 years (range 1.4–22.0 years). The control group 
consisted of patients with an average age of 65.0 years 
(range 30.6 – 92.9), that had been enrolled at ACTA for 
an average of 13.0 years, (range from 2.3-25.3 years). In 
the control group, also 89% of the subjects were female.
- Extractions
Patients with SS had a 61% higher risk of one or more 
extractions than patients in the control group (Table 1, 
Fig. 1). The mean number of extractions were signifi-
cantly higher in the SS group (3.18 ± 6.33 versus 0.77 ± 
1.77) versus the control group. These results were found 
both in the maxilla (1.75 ± 3.54 versus 0.38 ± 1.04) and 
the mandible (1.43 ± 3.11 versus 0.38 ± 1.04) (Table 2). 
Additionally, the number of extractions per sextant was 
significantly higher in the SS group when compared 
with the control group (Table 2). In the sextant 13-23 
the proportion of patients with at least one extraction 
(≥ 1) in the SS group was 3.4 times higher than in the 
control group, compared with 1.7-2.4 in the other sex-
tants. When comparing the pSS with the sSS patients, 
the sSS patients had significantly more often extractions 
in the anterior maxilla sextant 13-23 (p=0.03; chi2 test) 
(Table 3).
In the SS group, there was a non-significant tendency 
for more maxillary teeth to have been extracted than 
mandibular teeth (42:34). In the control group, the num-
ber of extractions in the maxilla and mandible were 
comparable (21:20).
Significantly more patients in the SS group (pSS + sSS) 
(14.8%) were edentulous compared to the control group 
(1.9%),  (p = 0.001).
- Medication 
In total 43.5% (n=47) of the patients in the SS group 
suffered from systemic disorders such as rheumatic dis-
eases. In the control group hypertension was the most 
common systemic disorder (20.0%), followed by car-
diovascular disease (13.1%) and hypercholesterolemia 
(12.1%). Medication was prescribed more frequently in 
the SS group than in the control group (Table 4).  SS 
patients frequently used prescription medication for 
cardiovascular, anti-inflammatory, gastrointestinal 
disorders and antidepressants. Patients diagnosed with 
SS more frequently used anti-inflammatory drugs (p < 
0.001); antidepressants (p < 0.001); diuretics (p = 0.009), 
thyroid medication (p = 0.03) or drugs that can induce a 
dry mouth than non-SS patients (Table 4).

































Table 1. Number of Sjögren’s syndrome patients and control subjects with  ≥1 extrac-
tion (s) distributed according to the location.






N = 108 Mann-Whitney
U Test P-valuemean Min Max mean Min Max
Total 0.77 0.0 10.0 3.18 0.0 0.28 0.001
Maxilla 0.38 0.0 7.0 1.75 0.0 14.0 0.003
14-17 0.13 0.0 2.0 0.47 0.0 4.0 0.011
13-23 0.10 0.0 3.0 0.77 0.0 6.0 0.001
24-27 0.15 0.0 3.0 0.50 0.0 4.0 0.012
Mandible 0.38 0.0 7.0 1.43 0.0 14.0 0.001
44-47 0.09 0.0 1.0 0.38 0.0 4.0 0.006
43-33 0.14 0.0 6.0 0.58 0.0 6.0 0.026
34-37 0.15 0.0 4.0 0.46 0.0 4.0 0.020
Table 2. Average number of extractions of Sjögren’s syndrome patients and control subjects,  distributed according to the location.
























Table 3. Number of patients with primary (pSS) and secondary Sjögren’s syn-
drome (sSS) with  ≥1 extraction (s) distributed according to the location.
Fig. 1. Number and location of extraction in the Sjögren’s syndrome patients and control subjects.
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Discussion 
This study demonstrated that SS patients are more 
prone to tooth loss than individuals not diagnosed with 
Sjögren’s syndrome. In addition, the results of this 
study shows that extractions are more prone in some 
area’s then in others with the highest number of extrac-
tions in the anterior maxilla. These results are in good 
agreement with a previous study on the prevalence of 
dental caries amongst SS patients (19). The same study 
reported that 63% of all study patients with SS were 
edentulous before the age of 45, compared to 10% in 
the control group. Another study reported that the num-
ber of missing or restored teeth was significantly higher 
in patients with SS than in a control group (23). The 
SS patients in our study were also more prone to lose 
their teeth over a shorter period of time than the control 
group. 
The earlier tooth loss observed in the SS group could be 
related to reduced salivary flow. In this context, a previ-
ous study on the effects of radiotherapy in the head and 
neck region demonstrated that reduced salivary flow 
commonly results in an increased susceptibility to car-
ies (24). Saliva promotes the remineralization of teeth 
and salivary proteins protect the enamel surface against 
erosion and caries. Furthermore, saliva has a buffering 
function, and contains enzymes and peptides with anti-
bacterial effects. In patients with SS, the salivary flow is 






Cardiovascular medications (*) 18 16.8%
16 
14.8% 0.686
Anti-inflammatory drugs (*) 1 0.9%
21 
19.4% 0.000
rheumatic medication 5 4.7%
13 
12.0% 0.051
stomach Medication 2 1.8%
15 
13.8% 0.001
antidepressants (*) - 13 12.0% 0.000
diuretics (*) 1 0.9%
9 
8.3% 0.009
thyroid medication (*) 1 0.9%
7 
6.5% 0.032
bisphosphonates (*) 1 0.9%
5 
4.6% 0.100
Dietary Supplements (*) 1 0.9%
4 
3.7% 0.178
analgetics - 4 3.7% 0.044
Anticonvulsants - 4 3.7% 0.045
antidiabetics (*) 1 0.9%
2 
1.8% 0.566
respiratory medication (*) 1 0.9%
2 
1.8% 0.566
antihistamines (*) 1 0.9%
1 
0.9% 1.000
(*) - Xerogenic medication with side effects or other negative side effects on the teeth.
Table 4. Medication use of Sjögren’s syndrome patients and control subjects.
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cosylation are also altered (25,26). This subsequently 
influences the protective characteristics of saliva, and 
its ability to protect and maintain oral health (27). Mul-
tiple studies have reported that mucins are especially 
vital for binding lubricants to oral surfaces (25,28,29). 
This not only prevents a sense of dry mouth (xerosto-
mia), but also inhibits bacteria from binding to oral 
surfaces. Moreover, patients suffering from SS have a 
reduced mucin concentration or functionally impaired 
mucins, which makes it easier for bacteria to attach to 
the oral surfaces and cause caries and infections. This 
might provide an explanation for the increased dental 
caries and early tooth loss in SS patients (25,28,29). Un-
fortunately, in this study salivary flow and composition 
were not available. 
The enhanced tooth loss observed in the SS patients 
could have resulted from periodontal problems. Previous 
studies reported conflicting results concerning the risk of 
periodontal disease in SS patients. A study focusing on 
plaque, bleeding and calculus indexes, as well as probing 
depth and attachment levels, reported no statistical dif-
ferences between SS patients and control patients (18). A 
similar study reported that SS patients had higher plaque 
index scores, higher decayed/missing/filled surface 
scores, increased alveolar bone loss, deeper clinical at-
tachment levels, and increased pockets. It was concluded 
that the risk of acquiring adult periodontitis was 2.2 times 
higher in SS patients than controls (17). A more recent 
study that focused on the prospective evaluation of dental 
and periodontal status in patients with suspected SS re-
ported that SS patients had a significantly higher plaque 
index and bleeding on probing. However, there was no 
significant difference in the probing depths between SS 
patients and control patients (16). Taken together, this in-
dicates that there is still no conclusive evidence that SS 
enhances periodontal disease. 
In addition to SS, certain classes of drugs can induce 
hypo-salivation by targeting neurotransmitters and re-
ceptors. Drugs that inhibit neurotransmitter binding to 
acinar membrane receptors or that interfere with ion 
transport pathways may negatively affect the quantity 
as well as the quality of saliva (30). Many of the drugs 
used by the SS patients and the control subjects in the 
present study may have had such an effect (Table 4). In 
the SS group, significantly more xerogenic drugs were 
used than in the control group. This might have further 
reduced the salivary flow rate in the SS patient group. 
Significant more teeth were lost in the anterior max-
illa of the sSS group compared to the anterior maxilla 
of the pSS group. This could be explained by the fact 
that the patients in the sSS group where significantly 
older than the pSS group. These results are similar to a 
study that reported tooth loss and edentulism increase 
with age (31). A second explanation could be that sSS is 
often associated with rheumatoid arthritis, which may 
negatively affect the oral health of these patients. In this 
context, a study reported that patients with rheumatoid 
arthritis have impaired mobility of the shoulders and 
wrists, which may subsequently affect oral care (32). 
Both age and impaired oral health could potentially 
contribute to the premature loss of teeth in patients with 
secondary SS. 
Noticeable is the similarity of the observed difference 
of the enhanced tooth loss in the anterior maxilla when 
both the SS groups are compared to the control patients. 
Several studies have found not only the lowest film 
velocities and biofilm in this region but also the low-
est stimulated amylase in the anterior regions (33-35). 
It could be hypothesized that if the anterior region of 
the maxilla is already the least lubricated region in nor-
mal patients, that this area is also the first to be affected 
when salivary flow decreases.
A potential limitation of the present study is that the 
included patients were treated in specialized dental cen-
ters to which patients are referred to for the treatment of 
more severe and/or oral problems. As a result, it could 
be hypothesized that the average number of extractions 
in our SS group is higher than the number of extractions 
in the average Sjögren patient. Another limitation is 
that most patient records lacked information on whether 
preventive oral care was provided, disease duration and 
salivary flow rates. This useful information was unfor-
tunately not available, and could not be measured due to 
the retrospective nature of our study.
Conclusion
In conclusion, the present study demonstrated that ex-
tractions are more frequent in SS patients compared 
with non-SS patients. In addition, the results of this 
study shows that extractions are more prone in some 
area’s then in others with the highest number of extrac-
tions in the anterior maxilla. Data collected in this study 
could contribute to the development of protocols for SS 
patients regarding oral hygiene as well as prosthodontic 
and implant treatments. 
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